Evaluation of Curcumin as NF-κB Inhibitor for Breast Cancer Therapy Using In Silico Approach

  • Endang Adillah Alauddin State Islamic University of Makassar
  • Nour Albahri Tishreen University
  • Shrouk Ekramy Al Azhar University
Keywords: Breast Cancer, Curcumin, In Silico Analysis, Molecular Docking, NF-κB

Abstract

Purpose of the study: This study aims to evaluate the potential of curcumin as a breast cancer therapeutic agent by analyzing its ability to inhibit NF-κB activation using an in silico approach, specifically through molecular docking to assess absorption and interaction with the target protein.

Methodology: This study used a quantitative experimental method with molecular docking as an in silico approach. Tools included a Lenovo laptop (Intel® Inside™, Windows 10 Pro). Software used: PyRx 0.8 (with AutoDock Vina), YASARA, PyMOL, and Discovery Studio 2019. Ligand data were obtained from PubChem; proteins from Protein Data Bank. Lipinski's Rule was applied for drug-likeness screening.

Main Findings: Curcumin showed a binding affinity of -6.2 kcal/mol to NF-κB with RMSD < 2.00 Å. Visualization confirmed hydrogen bonds at ASN 32 and ASN 47, and hydrophobic pi-alkyl interactions at ALA 34 and ARG 50. Lipinski's Rule of Five was fulfilled, indicating good oral drug-likeness and potential as an NF-κB inhibitor in breast cancer therapy.

Novelty/Originality of this study: This study offers new insights into the potential of curcumin as a natural NF-κB inhibitor for breast cancer therapy through a comprehensive in silico approach. By combining molecular docking, visualization, and drug-likeness analysis, it advances current knowledge by highlighting curcumin's binding efficiency and pharmacological feasibility, supporting its development as an alternative anticancer candidate.

References

H. Sung et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.

J. Ferlay et al., “Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods,” Int. J. Cancer, vol. 144, no. 8, pp. 1941–1953, Apr. 2019, doi: 10.1002/ijc.31937.

R. L. Siegel, T. B. Kratzer, A. N. Giaquinto, H. Sung, and A. Jemal, “Cancer statistics, 2025.,” CA. Cancer J. Clin., no. October 2024, pp. 10–45, 2025, doi: 10.3322/caac.21871.

Z. Li et al., “Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: the urgent need to address inequalities in cervical cancer,” Int. J. Cancer, vol. 157, no. 2, pp. 288–297, Jul. 2025, doi: 10.1002/ijc.35369.

W. Cao, K. Qin, F. Li, and W. Chen, “Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN),” J. Natl. Cancer Cent., vol. 4, no. 2, pp. 128–134, Jun. 2024, doi: 10.1016/j.jncc.2024.05.001.

A. K. Das, S. K. Biswas, A. Bhattacharya, and E. Alam, “Introduction to breast cancer and awareness,” in 2021 7th International Conference on Advanced Computing and Communication Systems (ICACCS), IEEE, Mar. 2021, pp. 227–232. doi: 10.1109/ICACCS51430.2021.9441686.

M. cancer is caused by the proliferation of abnormal cells in breast tissue that form a lumphammad Akram, M. Iqbal, M. Daniyal, and A. U. Khan, “Awareness and current knowledge of breast cancer,” Biol. Res., vol. 50, no. 1, pp. 1–23, 2017, doi: 10.1186/s40659-017-0140-9.

R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA. Cancer J. Clin., vol. 71, no. 1, pp. 7–33, Jan. 2021, doi: 10.3322/caac.21654.

J. Lopiccolo, A. Gusev, D. C. Christiani, and P. A. Jänne, “Lung cancer in patients who have never smoked — an emerging disease,” Nat Rev Clin Oncol, vol. 21, no. 2, pp. 121–146, 2024, doi: 10.1038/s41571-023-00844-0.Lung.

S. Łukasiewicz, M. Czeczelewski, A. Forma, J. Baj, R. Sitarz, and A. Stanisławek, “Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review,” Cancers (Basel)., vol. 13, no. 17, p. 4287, Aug. 2021, doi: 10.3390/cancers13174287.

R. Farghadani and R. Naidu, “Curcumin: modulator of key molecular signaling pathways in hormone-independent breast cancer,” Cancers (Basel)., vol. 13, no. 14, p. 3427, Jul. 2021, doi: 10.3390/cancers13143427.

S. S. Panda et al., “Design, synthesis, and molecular docking studies of curcumin hybrid conjugates as potential therapeutics for breast cancer,” Pharmaceuticals, vol. 15, no. 4, p. 451, Apr. 2022, doi: 10.3390/ph15040451.

Published
2025-07-03
How to Cite
Adillah, E., Albahri, N., & Ekramy, S. (2025). Evaluation of Curcumin as NF-κB Inhibitor for Breast Cancer Therapy Using In Silico Approach. Journal of Academic Biology and Biology Education, 2(1). https://doi.org/10.37251/jouabe.v2i1.1947
Section
Articles